EUCTR2020-003435-13-IT进行中（未招募）1 期
Metronomic vinorelbin, cyclophosphamide and capecitabine after progression to cyclin-dependent kinase 4/6 inhibitors for hormone receptors positive HER2 negative metastatic breast cancer - MARLENE
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 25 人开始时间: 2021年6月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male or female subjects with any menopausal status age = 18 years and has signed informed consent before any trial related activities are conducted;
- •-Subjects with histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy;
- •-Subjects must have ER-positive and/or PgR-positive, HER2-negative tumor status confirmed per local laboratory testing on their primary tumor or if available on their most recent biopsy from a metastatic lesion (if metastatic disease), or recurrent disease lesion (if locally advanced).
- •-Subjects must have one of the following as defined by RECIST v1.1 prior to start study treatment:
- •a.Measurable disease as per RECIST 1.1 criteria.
- •b.Non measurable (evaluable) bone-only disease.
- •-Subjects must be progressed on/after prior CDK4/6 inhibitor combination therapy with either fulvestrant or an AI and it must be the last therapy before the study entry;
- •-Subjects must not be candidates to further endocrine therapies or other combinations;
- •-Subjects may have previously received at least one and no more than two lines of endocrine therapy for advanced/metastatic breast cancer and meet the following criteria:
- •a.Last endocrine therapy to study entry must be given in combination with CDK4/6i;
- •b.Progression on or within eight weeks of ending treatment with each prior line of endocrine therapy (single agent or in combination) must be documented;
- •c.For subjects who progress during or within 12 months of adjuvant endocrine therapy, this may count as one line of treatment for advanced/metastatic disease;
- •d.In the absence of progression, adjuvant therapy does not count as one of the lines of endocrine therapy;
- •e.Endocrine therapy must be discontinued prior to study entry, excluding LH-RH analogue;
- •-Subjects may have received no more than one line of chemotherapy in the advanced/metastatic setting;
- •-Patients may have received any primary and/or adjuvant therapies. For subjects who progress within 12 months of (neo)adjuvant chemotherapy, this will count as one prior line of therapy for advanced/metastatic disease;
- •-Patients may have received metronomic capecitabine, methotrexate and cyclophosphamide or standard dose capecitabine in adjuvant setting at least 12 months before study entry;
- •-Previous treatment with capecitabine, cyclophosphamide and vinorelbine not in metronomic schedule for advanced disease is allowed, provided that the patient has progressive disease at study entry and the patients should not be defined as refractory” to treatments (PR o CR o SD > 6 months);
- •-Eastern Cooperative Oncology Group (ECOG) performance status = 2;
- •-Life expectancy of at least 12 weeks;
- •-Able to to swallow the study drug whole as a tablet
- •-Patient has adequate bone marrow and organ function;
- •-Confirmed negative serum pregnancy test (ß-hCG) within 72 hours before starting study treatment for patients with pre or peri-menopausal status.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Previous metronomic chemotherapy for advanced disease with capecitabine, cyclophosphamide and vinorelbine;
- •2. Patients defined as refractory” to capecitabine, cyclophosphamide and vinorelbine (PD o SD < 6 months);
- •3. Presence of symptomatic cerebral or leptomeningeal involvement;
- •4. Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix;
- •5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements;
- •6. Malabsorption syndrome or disease affecting significantly gastrointestinal function or major resection of the stomach or proximal small bowel that could affect absorption of oral vinorelbine;
- •7. Patients with known low or absent dihydropyrimidine dehydrogenase (DPD) activity;
- •8. History of severe and unexpected reactions to fluoropyrimidine therapy;
- •9. Concurrent treatment with any other anti-cancer therapy except LHRH analogue;
- •10. Patients with pre-existing motor or sensory peripheral neuropathy grade 2 according to National Cancer Institute criteria;
- •11. Major surgery within 28 days before the first dose of study drug;
- •12. Radiation therapy within 14 days (28 days for brain lesions per Exclusion Criterion 3) before the first dose of study drug. Note: tumor lesions previously subjected to radiation therapy or other locoregional therapy will be considered measurable only if disease progression after completion of locoregional therapy is clearly documented;
- •13. Any concurrent severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with compliance with study procedures or the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study;
- •14. Known hypersensitivity reaction to drugs chemically related to capecitabine, cyclophosphamide and vinorelbine or their excipients;
- •15. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test;
- •16. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are willing to use highly effective methods of birth control as determined to be acceptable by the principal investigator and sponsor during the study treatment and through 120 days after the last dose of study drug.
研究者
相似试验
进行中（未招募）
不适用
Adjunction with Capecitabin, Lapatinib and Vinorelbin to treat patients with HER2/new-positive, advanced or metastized breast cancer after failure of TrastuzumabFemale patients with HER2/new-positive, locally advanced or metastized breast cancer after failure of chemotherapy with TrastuzumabMedDRA version: 15.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017219-13-DEDeutsche Krebsgesellschaft Sponsor GmbH
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial'Diffuse Large-Bcell LymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-ITCELL THERAPEUTICS INC. SEDE SECONDARIA280
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) andCyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) inPatients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized,Multicenter, Comparative TrialDiffuse large B-cell lymphoma.MedDRA version: 13.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-DECell Therapeutics Europe S.r.l.280
进行中（未招募）
不适用
Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II studyEUCTR2011-004146-18-GBThe Royal Marsden NHS Foundation Trust186
进行中（未招募）
1 期
ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN STAGE III NON SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III STUDYEUCTR2004-005135-26-DEPierre Fabre Médicament376